Department of Clinical Sciences in Lund, Oncology and Pathology, Faculty of Medicine, Lund University Cancer Center / Kamprad, Lund University and Skåne University Hospital, Lund, Sweden.
Departments of Oncology and Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark.
Virchows Arch. 2020 Aug;477(2):317-320. doi: 10.1007/s00428-020-02768-x. Epub 2020 Feb 20.
Human epidermal growth factor receptor 2 (HER2) status in breast cancer is routinely determined through immunohistochemistry (IHC) and/or in situ hybridisation (ISH) performed on whole tissue sections (WS). The purpose was to evaluate whether a gene protein assay (GPA) combining IHC with ISH, performed on breast cancer tissue microarray (TMA), is suitable for large-scale retrospective HER2 status evaluation. TMAs from 606 tumours from a Swedish population-based cohort (2005-2012) were stained with GPA. GPA IHC on TMA yielded weaker staining than IHC on WS during routine pathological assessment (86.0% agreement). However, final HER2 status agreement between GPA on TMA and WS based on both IHC and ISH was 97.7%. Only 14 tumours were discordant and one tumour with IHC score 1+ on both TMA and WS was HER2 amplified on TMA. In conclusion, GPA on TMA is suitable for large-scale retrospective evaluation of HER2 status.
人表皮生长因子受体 2（HER2）在乳腺癌中的状态通常通过对全组织切片（WS）进行免疫组织化学（IHC）和/或原位杂交（ISH）来确定。目的是评估在乳腺癌组织微阵列（TMA）上进行的结合 IHC 和 ISH 的基因蛋白测定（GPA）是否适合大规模回顾性 HER2 状态评估。使用 GPA 对来自瑞典基于人群的队列（2005-2012 年）的 606 个肿瘤的 TMA 进行了染色。在常规病理评估中，TMA 上的 GPA IHC 染色比 WS 上的 IHC 染色弱（86.0%的一致性）。然而，基于 IHC 和 ISH，TMA 上的 GPA 和 WS 之间最终的 HER2 状态一致性为 97.7%。只有 14 个肿瘤存在差异，一个 TMA 和 WS 上的 IHC 评分均为 1+的肿瘤在 TMA 上呈 HER2 扩增。总之，TMA 上的 GPA 适合大规模回顾性 HER2 状态评估。
